US FDA approves Sun Pharmaceutical''s Novartis-equivalent generic Exelon capsules for US markets

24 Oct 2007

1
The US Foods and Drug Administration has granted its final approval for Sun Pharmaceutical''s abbreviated new drug application (ANDA) to market its generic version of Novartis Exelon, rivastigmine tartrate capsules.

These generic rivastigmine capsules are AB-rated equivalent of Novartis Exelon Capsules and include four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). These strengths of Exelon® have annual sales of approximately USD 200 million in the US.

Sun Pharma, being one of the first-to-file an ANDA for generic Exelon with a para IV certification, shares a 180-day marketing exclusivity, in view of the ongoing litigation with Novartis on this product, and is evaluating its launch options.
Rivastgmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer''s type and for the treatment of mild to moderate dementia associated with Parkinson''s disease.

Business History Videos

History of hovercraft Part 3 | Industry study | Business History

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2 | Industry study | Business History

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1 | Industry study | Business History

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | Industry study | Business History

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more
View details about the software product Informachine News Trackers